Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Disclosure Statements In Testimonial Ads Largely Ineffective – FTC Studies

This article was originally published in The Tan Sheet

Executive Summary

Results from two studies funded by the Federal Trade Commission show disclosure statements for dietary supplements are largely ineffective in helping consumers understand product efficacy claims after they view testimonial advertisements

You may also be interested in...



FTC Testimonial Guidelines Say Advertisers Must Show Typical Outcomes

Revised Federal Trade Commission guidelines on endorsements and testimonials will not have a chilling effect on advertising as long as marketers using anecdotal testimonials provide information on what typical outcomes are, according to an FTC executive

FTC Testimonial Guidelines Say Advertisers Must Show Typical Outcomes

Revised Federal Trade Commission guidelines on endorsements and testimonials will not have a chilling effect on advertising as long as marketers using anecdotal testimonials provide information on what typical outcomes are, according to an FTC executive

FTC Testimonial Guidelines Say Advertisers Must Show Typical Outcomes

Revised Federal Trade Commission guidelines on endorsements and testimonials will not have a chilling effect on advertising as long as marketers using anecdotal testimonials provide information on what typical outcomes are, according to an FTC executive

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel